Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2020)
Historic Net Cash Flow for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to $5.4 million.
- Monopar Therapeutics' Net Cash Flow rose 96733.49% to $5.4 million in Q3 2020 from the same period last year, while for Sep 2020 it was $13.5 million, marking a year-over-year increase of 53308.33%. This contributed to the annual value of $38.5 million for FY2024, which is 436756.86% up from last year.
- Monopar Therapeutics' Net Cash Flow amounted to $5.4 million in Q3 2020, which was up 96733.49% from -$49070.0 recorded in Q2 2020.
- Monopar Therapeutics' 5-year Net Cash Flow high stood at $8.7 million for Q4 2019, and its period low was -$1.0 million during Q1 2019.
- In the last 4 years, Monopar Therapeutics' Net Cash Flow had a median value of -$617526.0 in 2020 and averaged $1.0 million.
- Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 21920.85% in 2018, then skyrocketed by 130170.65% in 2019.
- Monopar Therapeutics' Net Cash Flow (Quarter) stood at -$806020.0 in 2017, then grew by 9.99% to -$725482.0 in 2018, then skyrocketed by 1301.71% to $8.7 million in 2019, then crashed by 37.67% to $5.4 million in 2020.
- Its Net Cash Flow was $5.4 million in Q3 2020, compared to -$49070.0 in Q2 2020 and -$617526.0 in Q1 2020.